Genuine Parts schedules third-quarter results release and conference call

KS Industry held an extraordinary shareholder meeting on Oct. 8, 2026. Shareholders passed resolutions to appoint Kim In-gyeom as an internal director. Approval was also secured to appoint Chen Yang as an internal director. Resolutions to appoint Kim Woo-joon, Cha Haeng-jeon as independent directors were adopted. The votes authorized these board appointments; the filing did not confirm the appointments have been implemented. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KS Industry Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008900252), on October 08, 2026, and is solely responsible for the information contained therein.

Pfizer (PFE.US) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved its tyrosine kinase inhibitor, Tukysa (tucatinib), as part of a combination regimen for first-line maintenance treatment of a certain type of breast cancer.